Dimensional Fund Advisors LP increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% in the 4th quarter, HoldingsChannel reports. The fund owned 2,978,445 shares of the medical equipment provider’s stock after acquiring an additional 51,606 shares during the period. Dimensional Fund Advisors LP’s holdings in Boston Scientific were worth $105,251,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. We Are One Seven LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $27,000. Athena Capital Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $28,000. Ipswich Investment Management Co. Inc. bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $28,000. CWM LLC raised its stake in shares of Boston Scientific by 54.3% during the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 359 shares in the last quarter. Finally, Exane Derivatives raised its stake in shares of Boston Scientific by 116,300.0% during the 4th quarter. Exane Derivatives now owns 1,164 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 1,163 shares in the last quarter. Hedge funds and other institutional investors own 91.43% of the company’s stock.
Several research analysts recently commented on BSX shares. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday, April 25th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price objective on shares of Boston Scientific in a research note on Monday. Canaccord Genuity reduced their price objective on shares of Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Evercore ISI upgraded shares of Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 price objective for the company in a research note on Monday. Finally, Guggenheim reiterated a “buy” rating and set a $48.00 price objective on shares of Boston Scientific in a research note on Friday, February 8th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $41.53.
Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.01). The company had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.54 billion. Boston Scientific had a return on equity of 24.65% and a net margin of 18.08%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 EPS. On average, equities research analysts expect that Boston Scientific Co. will post 1.55 earnings per share for the current year.
In other news, SVP Maulik Nanavaty sold 3,039 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $40.32, for a total value of $122,532.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 64,223 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $40.84, for a total transaction of $2,622,867.32. The disclosure for this sale can be found here. Insiders sold a total of 275,678 shares of company stock worth $11,038,872 over the last ninety days. Insiders own 0.66% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://weekherald.com/2019/05/16/boston-scientific-co-bsx-position-lifted-by-dimensional-fund-advisors-lp.html.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: What is a short straddle?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.